| US 7,514,449 B2 | ||
| Fused furan compound | ||
| Takayuki Kawaguchi, Tokyo-to (Japan); Hidenori Akatsuka, Toda (Japan); Toru Iijima, Toda (Japan); Tatsuya Watanabe, Koganei (Japan); Jun Murakami, Saitama (Japan); and Takashi Mitsui, Nishitokyo (Japan) | ||
| Assigned to Mitsubishi Tanabe Pharma Corporation, Osaka-shi (Japan) | ||
| Appl. No. 10/540,878 PCT Filed Jan. 08, 2004, PCT No. PCT/JP2004/000074 § 371(c)(1), (2), (4) Date Jun. 27, 2005, PCT Pub. No. WO2004/063202, PCT Pub. Date Jul. 29, 2004. |
||
| Claims priority of application No. 2003-003536 (JP), filed on Jan. 09, 2003; and application No. 2003-334598 (JP), filed on Sep. 26, 2003. | ||
| Prior Publication US 2006/0094724 A1, May 04, 2006 | ||
| Int. Cl. A61K 31/444 (2006.01); C07D 491/048 (2006.01) | ||
| U.S. Cl. 514—302 [546/115] | 20 Claims |
1. A condensed furan compound of the formula (I):
   Y is an optionally substituted amino; an optionally substituted cycloalkyl; an optional substituted aryl; an optionally substituted
saturated heterocyclic group; or an optionally substituted unsaturated heterocyclic group;
A is a single bond; an alkylene optionally substituted by oxo; an alkenylene; an alkenylidene; or an oxygen atom;
R1A, R1B are the same or different and each is hydrogen; a halogen; an alkyl; a haloalkyl; an alkoxy; cyano; nitro; or an optionally
substituted amino;
R2A, R2B are the same or different and each is hydrogen; a halogen; an optionally substituted alkyl; an optionally substituted alkoxy;
an optionally substituted amino; nitro; cyano; hydroxy; carboxy; an optionally substituted alkoxycarbonyl; an optionally substituted
carbamoyl; a carbonyl substituted by an optionally substituted saturated heterocyclic group; an optionally substituted saturated
heterocyclic group; aryl; or an optionally substituted unsaturated heterocyclic group;
R3 is hydrogen or an alkyl; and
R4is hydrogen or an alkyl,
or a pharmaceutically acceptable salt thereof.
|